Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials

Statistics in Medicine

Volumn 24, Issue 10, 2005, Pages 1509-1524

  Panhard, Xavière ^a   Mentré, France ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

THEOPHYLLINE;

ANALYTICAL ERROR; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; BIOEQUIVALENCE; CLINICAL TRIAL; COMPARTMENT MODEL; DATA ANALYSIS; DOSE RESPONSE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MECHANISM; DRUG RESEARCH; HUMAN; MATHEMATICAL COMPUTING; MONTE CARLO METHOD; NONPARAMETRIC TEST; PARAMETRIC TEST; POPULATION MODEL; SIMULATION; STATISTICAL ANALYSIS; STATISTICAL MODEL; STEADY STATE;

AREA UNDER CURVE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FRANCE; HUMANS; MODELS, STATISTICAL; NONLINEAR DYNAMICS; THEOPHYLLINE; THERAPEUTIC EQUIVALENCY;

EID: 19144365774     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.2047     Document Type: Article

References (25)

1. FDA. Guidance for Industry - Population Pharmacokinetic. 1999. http://www.fda.gov/cder/guidance/1852fnl.pdf
2. EMEA. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. 2000. http://www.emea.eu.int/pdfs/human/ewp/140198en.pdf
3. EMEA. Note for Guidance on the Investigation of Drug Interactions. 1998. http://www.emea.eu.int/pdfs/human/ewp /056095en.pdf
4. Gabrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications (3rd edn). Apotekarsocieteten: Stockholm, 2000.
5. Sheiner LB, Wakefield J. Population modeling in drug development. Statistical Methods in Medical Research 1999; 8:183-193.
6. Mentré F, Dubruc C, Thénot JP. Population pharmacokinetic analysis and optimisation of the experimental design for mizolastine solution in children. Journal of Pharmacokinetics and Biopharmaceutics 2001; 28:299-319.
7. Barry M et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clinical Pharmacokinetics 1999; 36:289-304.
8. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annual Review of Pharmacology and Toxicology 2000; 40:67-95.
9. Comets E, Mentré F. Evaluation of tests based on individual versus population modelling to compare dissolution curves. Journal of Biopharmaceutics and Statistics 2001; 11:107-123.
10. Wu H, Wu L. Identification of significant host factors for HIV dynamics modelled by non-linear mixed-effects models. Statistics in Medicine 2002; 21:753-771.
11. Wählby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. Journal of Pharmacokinetics and Pharmacodynamics 2001; 28:231-252.
12. Bois FY, Tozer TN, Hauck WW, Chen ML, Patnaik R, Williams RL. Bioequivalence: performance of several measures of extent of absorption. Pharmacological Research 1994; 11:715-722.
13. Kowalski KG, Hutmacher MM. Efficient screening of covariates in population models using Wald's approximation to the Likelihood Ratio Test. Journal of Pharmacokinetics and Pharmacodynamics 2001; 28:253-275.
14. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics 1987; 15:657-680.
15. Chow SC, Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies. Marcel Dekker: New York, 1999.
16. Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for statistical analyses of bioequivalence studies. International Journal of Clinical Pharmacology Therapeutics and Toxicology 1990; 28:72-78.
17. Pinheiro JC, Bates DM. Mixed-effect Models in S and Splus. Springer: New York, 2000.
18. Boeckmann AJ, Sheiner LB, Beal SL. NONMEM users guide: part V. Technical Report, NONMEM Project Group, University of California, San Fransisco, 1994.
19. Lindström MJ, Bates DM. Nonlinear mixed-effects models for repeated measures data. Biometrics 1990; 46:673-687.
20. Machin D, Campbell M, Fayers P, Pinol A. Sample Size Tables for Clinical Studies (2nd edn). Blackwell Science: Oxford, 1997.
21. Chow SC, Wang H. On sample size calculation in bioequivalence trials. Journal of Pharmacokinetics and Pharmacodynamics 2001; 28:155-168.
22. Retout S, Mentré F. Optimisation of individual and population designs using Splus. Journal of Pharmacokinetics and Pharmacodynamics 2003; 30:417-443.
23. Berger L, Hsu J. Bioequivalence trials, intersection-union tests and equivalence confidence sets (with discussion). Statistical Science 1996; 11:283-319.
24. Hauck WW, Hauschke D, Diletti E, Bois FY, Steinijans VW, Anderson S. Choice of Student's t or Wilcoxon based confidence intervals for assessment of average bioequivalence. Journal of Biopharmaceutics and Statistics 1997; 7:179-189.
25. Vonesh EF. A note on the use of Laplace's approximation for nonlinear mixed-effects models. Biometrika 1996; 83:447-452.